Jeff Sharman

13PUBLICATIONS
52CO-AUTHORS
Cancer therapy (excl. chemotherapy and radiation therapy)Haematological tumoursNuclear medicineMolecular targetsCardiology (incl. cardiovascular diseases)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (13)

|Sep 24, 2025
Five-Year Outcomes of the POLARIX Study Comparing Pola-R-CHP and R-CHOP in Patients With Diffuse Large B-Cell Lymphoma.

Franck Morschhauser, Gilles Salles, Laurie H Sehn

|Jun 06, 2025
Phase III Trial of Pirtobrutinib Versus Idelalisib/Rituximab or Bendamustine/Rituximab in Covalent Bruton Tyrosine Kinase Inhibitor-Pretreated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (BRUIN CLL-321).

Jeff P Sharman, Talha Munir, Sebastian Grosicki

|May 28, 2025
Care Coordination for Mosunetuzumab Therapy in Patients With Follicular Lymphoma in Community Practices: Learnings From the MorningSun Study Investigators.

Tara Graff, Ian Flinn, Jeff P Sharman

|Apr 18, 2024
Analysis of ventricular arrhythmias and sudden death from prospective, randomized clinical trials of acalabrutinib.

Jeff P Sharman, Paolo Ghia, Paulo Miranda

|Sep 14, 2022
MAJIC: a phase III trial of acalabrutinib + venetoclax versus venetoclax + obinutuzumab in previously untreated chronic lymphocytic leukemia or small lymphocytic lymphoma.

Christine E Ryan, Matthew S Davids, Richard Hermann

|Jul 18, 2022
Longitudinal health-related quality of life in first-line treated patients with chronic lymphocytic leukemia: Results from the Connect® CLL Registry.

Jeff P Sharman, Kim Cocks, Chadi Nabhan

Pageof 3

Frequent Collaborators

4 joint publications

Paolo Ghia

2 joint publications

Wojciech Jurczak

2 joint publications

John M Pagel

2 joint publications

Ian W Flinn